Wada Kiriko, Maeda Kunihiko, Tajima Katsushi, Kato Takeo, Kobata Tetsuji, Yamakawa Mitsunori
Department of Pathology, Yamagata University School of Medicine, Yamagata, Japan.
Histopathology. 2009 Jan;54(2):221-32. doi: 10.1111/j.1365-2559.2008.03203.x.
The receptor for B-cell-activating factor belonging to the tumour necrosis factor family (BAFF-R) and transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) have been established as binding molecules to BAFF. The aim of this study was to determine the pathological diagnostic roles and clinical significance of these BAFF-binding receptors in B-cell neoplasms.
Expression of BAFF-R and TACI was examined immunohistochemically in reactive lymphoid tissues and B-cell lymphomas including diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), mantle cell lymphoma (MCL), marginal zone B-cell lymphoma (MZBCL) and plasma cell myeloma (PCM). In reactive tissues BAFF-R was expressed exclusively in the cells of the mantle zone and within the germinal centres (GCs), whereas TACI appeared positive in the scattered cells in extrafollicular areas. There were variable patterns of expression of BAFF-R and TACI amongst the different types of B-cell lymphomas (MCL and FL: BAFF-R+TACI-; PCM: BAFF-R-TACI+; DLBCL and MZBCL: variable expression). Reverse transcriptase-polymerase chain reaction studies supported these results. The overall survival of the BAFF-R+ DLBCL group was significantly better than that of the BAFF-R- group.
These results indicate that the assessment of expression of BAFF-binding receptors aids subclassification and prognostication of DLBCL.
肿瘤坏死因子家族B细胞活化因子受体(BAFF-R)以及跨膜激活剂和钙调蛋白及亲环素配体相互作用分子(TACI)已被确认为BAFF的结合分子。本研究旨在确定这些BAFF结合受体在B细胞肿瘤中的病理诊断作用及临床意义。
采用免疫组织化学方法检测反应性淋巴组织以及包括弥漫性大B细胞淋巴瘤(DLBCL)、滤泡性淋巴瘤(FL)、套细胞淋巴瘤(MCL)、边缘区B细胞淋巴瘤(MZBCL)和浆细胞骨髓瘤(PCM)在内的B细胞淋巴瘤中BAFF-R和TACI的表达情况。在反应性组织中,BAFF-R仅在套区细胞和生发中心(GCs)内表达,而TACI在滤泡外区域的散在细胞中呈阳性。不同类型的B细胞淋巴瘤中BAFF-R和TACI的表达模式各不相同(MCL和FL:BAFF-R+TACI-;PCM:BAFF-R-TACI+;DLBCL和MZBCL:表达情况各异)。逆转录聚合酶链反应研究支持了这些结果。BAFF-R阳性的DLBCL组的总生存期明显优于BAFF-R阴性组。
这些结果表明,评估BAFF结合受体的表达有助于DLBCL的亚分类和预后判断。